An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis

Area of Science:

• Neuroimmunology
• Neurology
• Immunotherapy

Background:

• Voltage-gated potassium channel antibody-positive limbic encephalitis (VGKC+LE) is a rare autoimmune neurological disorder.
• Optimal immunotherapy for VGKC+LE remains undetermined, necessitating research into effective treatment regimens.

Purpose of the Study:

• To evaluate the effectiveness of a specific combination immunomodulatory regimen for treating VGKC+LE.
• To assess the clinical, cognitive, radiological, and immunological outcomes in patients receiving the proposed immunotherapy.

Main Methods:

• An open-label prospective study involving nine VGKC+LE patients.
• Treatment included plasma exchange, intravenous immunoglobulin, methylprednisolone, and oral prednisolone, with mycophenolate used in some.
• Serial assessments of clinical status, cognitive function, brain MRI, and VGKC antibody levels were performed.

Main Results:

• Rapid remission of seizures and hyponatraemia within one week was observed in all affected patients.
• Significant improvements in cognitive function occurred within three months, and MRI findings showed substantial recovery within nine months.
• All patients achieved immunological remission with normalized VGKC antibody titers within 1-4 months; one patient remained in remission 26 months after treatment cessation.

Conclusions:

• The studied combination immunotherapy regimen demonstrated efficacy in treating the clinical, cognitive, and immunological manifestations of VGKC+LE.
• Radiological improvements were noted in the majority of patients, supporting the regimen's therapeutic value.
• This regimen is proposed as a treatment option for VGKC+LE pending further randomized controlled trials.